Clinical and epidemiological characterization of covid-19 patients
DOI:
https://doi.org/10.35381/s.v.v8i1.3989Keywords:
Coronavirus infections, coronavirus, isolation and purification, (Source: DeCS)Abstract
Objective: To carry out a clinical and epidemiological characterization of patients with COVID-19. Methods: Descriptive observational. Results: The prevalence of confirmed cases showed a marked decrease from 41.65% in 2020 to 16.58% in 2022, suggesting a number of factors that may have influenced this reduction. Conclusion: In total, 5653 patients presented during the three years, of which 29.54% were confirmed cases of COVID-19, of the 5712 patients who attended the public health unit, 874 died, representing 15.46% of the total population studied.
Downloads
References
Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615.
Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416.
Thompson MG, et al. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. N Engl J Med. 2021;385(15):1355-1371.
Williamson EJ, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436.
Petrilli CM, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.
Barron E, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-822.
Clark A, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003-e1017.
Jordan RE, et al. COVID-19: risk factors for severe disease and death. BMJ. 2020;368:m1198.
Docherty AB, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterization Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
Grasselli G, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581.
Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-2059.
Flaxman S, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257-261.
Ioannidis JPA. The infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ. 2021;99(1):19-33.
Hall VJ, et al. Effectiveness of BNT162b2 mRNA vaccine against infection and COVID-19 vaccine coverage in healthcare workers in England, multicenter prospective cohort study (the SIREN Study). Lancet. 2021;397(10286):1725-1735.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Alice Mishell Mantilla-Moreira , Francisco Gabriel Morejón-Vallejo, Estefanny Mishell Santa Cruz-Alvarez , Blanca Cristina Estrella-Lopez
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
